Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-12-12
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies sirolimus, idarubicin, and cytarabine in treating patients
with newly diagnosed acute myeloid leukemia. Sirolimus may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either
by killing the cells or by stopping them from dividing. Giving sirolimus together with
idarubicin and cytarabine may kill more cancer cells.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University